# Our Statement of Intent

We will maintain a **broad portfolio** that maximises patient impact.

We will learn as much as we can from the patients on our trials.

---

### Statement of Intent

- Support a broad portfolio of clinical research that includes a range of **modalities** and **disease sites**, including rare cancers, and maximises patient impact.
- Prioritise investment in trials studying **CRUK Cancers of Unmet Need**.
- Support a balance of trials conducted in **early, pre-invasive, localised disease and metastatic** settings in order to improve patient outcomes.
- Invest more in promising, high impact, innovative **early phase** and **first-in-man** trials that would not progress otherwise.
- Act decisively as we **proactively manage** our portfolio.
- Seek opportunities to build and leverage commercial partnerships that accelerate the development of innovative **treatments and research**.

### Supporting Statements

- Prioritise our investment into scientifically-driven studies that use and analyse biomarkers and imaging, producing valuable **biological and clinical information** that will optimise treatments.
- Prioritise hypothesis-driven, data-rich, **sample collections** that support the discovery, validation and qualification of valuable biological information.
- Grow investment in **innovative, cost-effective trial designs** (e.g. basket trials, umbrella protocols, adaptive trials) that can be supported by strategic long-term investments in trial platforms.
- Encourage investigators to innovate, and selectively **accept greater scientific uncertainty** in trials where potential impact is high.\(^1\)

---

\(^1\) Examples include (i) CDD’s first-in-class experimental medicine trial (Mov18 IgE trial) where the target is not new (folate receptor) but it is the first time an IgE class antibody has been tested for cancer therapy, and (ii) using targeted therapies in early stage cancers when there are likely to be less driver mutations to target.